NLSPW
Income statement / Annual
Last year (2023), NLS Pharmaceutics AG's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, NLS Pharmaceutics AG's net income was -$12.17 M.
See NLS Pharmaceutics AG,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$11,408.00
|
$11,408.00
|
$10,050.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
-$11,408.00
|
-$11,408.00
|
-$10,050.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$5.91 M
|
$8.98 M
|
$5.92 M
|
$99,580.00
|
$1.70 M
|
$708.46
|
$4.32 M
|
General & Administrative Expenses |
$5.90 M
|
$6,505.72
|
$5,941.17
|
$2,199.79
|
$3.30 M
|
$2,740.41
|
$1.44 M
|
Selling & Marketing Expenses |
$0.00
|
$6.49 M
|
$5.93 M
|
$2.20 M
|
$2.49 M
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$5.90 M
|
$6.49 M
|
$5.93 M
|
$2.20 M
|
$2.49 M
|
$2,740.41
|
$1.44 M
|
Other Expenses |
$0.00
|
$10,045.00
|
-$17,323.00
|
-$328,365.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$11.81 M
|
$15.47 M
|
$11.85 M
|
$2.30 M
|
$4.20 M
|
$3,448.86
|
$5.77 M
|
Cost And Expenses |
$11.81 M
|
$15.48 M
|
$11.86 M
|
$2.30 M
|
$4.20 M
|
$3,448.86
|
$5.77 M
|
Interest Income |
$0.00
|
$100.87
|
$68.13
|
$233.70
|
$819.71
|
$0.00
|
$890.40
|
Interest Expense |
$145,153.00
|
$100,866.00
|
$68,134.00
|
$233,700.00
|
$819,711.00
|
$0.00
|
$890,403.00
|
Depreciation & Amortization |
$11,408.00
|
$11,408.00
|
$10,050.00
|
$2.30 M
|
$4.20 M
|
$3,448.86
|
$5.77 M
|
EBITDA |
-$11.80 M |
-$15.47 M |
-$11.85 M |
$0.00 |
-$430,400.00 |
$0.00 |
-$5.77 M |
EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
-$364,966.00
|
-$1.01 M
|
-$85,457.00
|
-$562,065.00
|
-$1.25 M
|
-$1,697.91
|
-$890,403.00
|
Income Before Tax |
-$12.17 M
|
-$16.50 M
|
-$11.95 M
|
-$2.86 M
|
-$5.45 M
|
-$5,146.77
|
-$6.66 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.00
|
$2.00
|
-$226,508.00
|
-$2,299.37
|
-$4,197.04
|
$0.00
|
-$5,766.72
|
Net Income |
-$12.17 M
|
-$16.50 M
|
-$11.95 M
|
-$2.86 M
|
-$5.45 M
|
-$5,146.77
|
-$6.66 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-0.32 |
-0.84 |
-0.81 |
-0.59 |
-0.49 |
-32.99 |
-0.57 |
EPS Diluted |
-0.32 |
-0.84 |
-0.81 |
-0.59 |
-0.49 |
-32.99 |
-0.57 |
Weighted Average Shares Out |
$38.18 M
|
$19.68 M
|
$14.75 M
|
$4.82 M
|
$11.14 M
|
$156.00
|
$11.78 M
|
Weighted Average Shares Out Diluted |
$38.18 M
|
$19.68 M
|
$14.75 M
|
$4.82 M
|
$11.14 M
|
$156.00
|
$11.78 M
|
Link |
|
|
|
|
|
|
|